Health · Healthcare & Policy · 2 hrs ago
Japan ministry questions data behind Tavneos approval
Japan’s health ministry has questioned the reliability of data used to approve Tavneos.
Tavneos was approved by the ministry and launched in Japan in 2022.
The drug’s package insert lists liver dysfunction as a serious side effect.
The ministry’s concern is about the reliability of the approval data.
The available information does not say what prompted the questions.
It also does not say what the ministry will do next.
Japan’s health ministry is questioning the reliability of data behind Tavneos’ approval.
Tavneos was approved by the ministry and launched in Japan in 2022.
The drug’s package insert listed liver dysfunction as a serious side effect.
The source does not state what prompted the ministry’s questions or when they were raised.
- Who
- Japan’s health ministry.
- What
- It is questioning the reliability of data behind Tavneos’ approval.
- When
- Not stated. Tavneos was approved and launched in Japan in 2022.
- Where
- Japan.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Tavneos
- Approval and launch
- Japan, 2022
- Ministry
- Japan’s health ministry
- Serious side effect listed
- Liver dysfunction